PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy

Phase 2 Completed 57 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Ortho Biotech Clinical Affairs, L.L.C. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness and safety of Epoetin alfa administered at 60,000 Units every two weeks in cancer patients who are not receiving chemotherapy or radiation therapy.

Timeline

Start: 2004-02
Primary completion: —
Completion: 2005-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	epoetin alfa	Protein / enzyme biologic	60000 iu	Subcutaneous

PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy

Summary

Timeline

Drugs

Indications